Total Payments
$138,828
2024 Payments
$24,443
Companies
20
Transactions
250
Medicare Patients
254
Medicare Billing
$48,804
Payment Breakdown by Category
Consulting$65,501 (47.2%)
Other$42,630 (30.7%)
Research$14,002 (10.1%)
Travel$9,616 (6.9%)
Food & Beverage$7,039 (5.1%)
Education$40.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $65,501 | 17 | 47.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,230 | 32 | 27.5% |
| Unspecified | $14,002 | 10 | 10.1% |
| Travel and Lodging | $9,616 | 24 | 6.9% |
| Food and Beverage | $7,039 | 164 | 5.1% |
| Honoraria | $4,400 | 2 | 3.2% |
| Education | $40.00 | 1 | 0.0% |
Payments by Type
General
$124,826
240 transactions
Research
$14,002
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $35,960 | 21 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $19,893 | 69 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $19,085 | 20 | $0 (2024) |
| Genentech USA, Inc. | $18,780 | 16 | $0 (2024) |
| F. Hoffmann-La Roche AG | $18,631 | 24 | $0 (2023) |
| Celgene Corporation | $13,953 | 22 | $0 (2022) |
| Horizon Therapeutics plc | $5,161 | 15 | $0 (2023) |
| Biogen, Inc. | $3,858 | 13 | $0 (2024) |
| Amgen Inc. | $1,250 | 10 | $0 (2024) |
| TG Therapeutics, Inc. | $1,140 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,443 | 35 | GENZYME CORPORATION ($21,192) |
| 2023 | $13,579 | 50 | F. Hoffmann-La Roche AG ($5,739) |
| 2022 | $4,920 | 20 | Genentech USA, Inc. ($4,328) |
| 2021 | $11,925 | 17 | Genentech USA, Inc. ($6,095) |
| 2020 | $18,773 | 31 | Celgene Corporation ($8,375) |
| 2019 | $32,133 | 57 | Alexion Pharmaceuticals, Inc. ($13,555) |
| 2018 | $14,879 | 18 | Novartis Pharmaceuticals Corporation ($7,269) |
| 2017 | $18,177 | 22 | GENZYME CORPORATION ($10,396) |
All Payment Transactions
250 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: Immunology | ||||||
| 11/08/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $18,123.00 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $457.04 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $265.00 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $190.26 | General |
| 10/16/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Neurology | ||||||
| 10/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $3.56 | General |
| Category: Rare Disease | ||||||
| 09/25/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Immunology | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $7.55 | General |
| Category: Neurology | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $2.34 | General |
| Category: Neurology | ||||||
| 08/14/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: Neurology | ||||||
| 07/26/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $76.44 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/25/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $33.97 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/24/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Neurology | ||||||
| 07/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $70.52 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/17/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $4.72 | General |
| Category: Neurology | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $78.22 | General |
| Category: Neurology | ||||||
| 06/28/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $31.65 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/27/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: Immunology | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Neurology | ||||||
| 06/13/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $118.58 | General |
| Category: Immunology | ||||||
| 05/31/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $130.29 | General |
| Category: Neurology | ||||||
| 05/30/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $136.65 | General |
| 05/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: Neurology | ||||||
| 05/12/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,157.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Prospective Pilot Study to Evaluate the Feasibility of Conducting Remote Patient Monitoring With the Use of Digital Technology in Patients With Multiple Sclerosis | F. Hoffmann-La Roche AG | $7,257 | 3 |
| NEURAL CORRELATES OF HAND MOTOR FUNCTION REVEALED BY STRUCTURAL MR IMAGING A SMARTPHONE-BASED REMOTE ASSESSMENT STUDY IN PEOPLE WITH MS | F. Hoffmann-La Roche AG | $2,525 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $2,188 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,435 | 3 |
| A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders. | Amgen Inc. | $597.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 101 | 146 | $75,846 | $18,628 |
| 2022 | 3 | 80 | 147 | $69,749 | $17,112 |
| 2021 | 2 | 49 | 68 | $35,240 | $9,118 |
| 2020 | 1 | 24 | 34 | $15,266 | $3,947 |
Total Patients
254
Total Services
395
Medicare Billing
$48,804
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 62 | $33,666 | $8,679 | 25.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 48 | $17,040 | $4,648 | 27.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 24 | $16,512 | $3,329 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $8,628 | $1,973 | 22.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 39 | 58 | $31,494 | $7,896 | 25.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 69 | $24,495 | $5,900 | 24.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $13,760 | $3,316 | 24.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 33 | 51 | $24,700 | $6,271 | 25.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 17 | $10,540 | $2,847 | 27.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 24 | 34 | $15,266 | $3,947 | 25.9% |
About Dr. Jennifer Graves, MD
Dr. Jennifer Graves, MD is a Neurology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1992849863.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Graves, MD has received a total of $138,828 in payments from pharmaceutical and medical device companies, with $24,443 received in 2024. These payments were reported across 250 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($65,501).
As a Medicare-enrolled provider, Graves has provided services to 254 Medicare beneficiaries, totaling 395 services with total Medicare billing of $48,804. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location San Diego, CA
- Active Since 02/16/2007
- Last Updated 07/18/2018
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1992849863
Products in Payments
- OCREVUS (Biological) $24,421
- DISEASE STATE (Drug) $10,392
- ZEPOSIA (Drug) $9,005
- GILENYA (Drug) $7,447
- Ocrevus (Biological) $7,275
- Non-Covered Product (Drug) $5,589
- UPLIZNA (Drug) $5,161
- Soliris (Drug) $4,180
- NO PRODUCT DISCUSSED (Drug) $2,595
- ARZERRA (Drug) $2,188
- BRIUMVI (Drug) $1,009
- UPLIZNA (Biological) $875.59
- KESIMPTA (Drug) $799.91
- ULTOMIRIS (Biological) $673.56
- TYSABRI (Biological) $309.75
- APTIOM (Drug) $260.23
- LUMAKRAS (Drug) $252.00
- MAYZENT (Drug) $240.67
- Kyprolis (Drug) $122.22
- ACTHAR (Biological) $99.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in San Diego
Dr. Revere Kinkel, M.d, M.D
Neurology — Payments: $432,113
Neurology $432,113
Dr. Hossein Ansari, M.d, M.D
Neurology — Payments: $431,759
Neurology $431,759
Nathaniel Schuster, M.d, M.D
Neurology — Payments: $313,162
Neurology $313,162
Dr. Monali Patel, M.d, M.D
Neurology — Payments: $251,383
Neurology $251,383
Dr. Jose Soria-Lopez, Md, MD
Neurology — Payments: $108,135
Neurology $108,135
Dr. Royya Modir, M.d, M.D
Neurology — Payments: $101,774
Neurology $101,774